Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection

Morita, Takahiro; Kurihara, Hiroaki; Hiroi, Kenta; Honda, Natsuki; Igaki, Hiroshi; Hatazawa, Jun; Itami, Jun

doi:10.1186/s13014-017-0949-y

Cited by 21 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described in section “ Tumor accumulation of 18 F-FBPA and PET imaging ”, melanomas in animal models showed higher uptake of 18 F-FBPA than non-melanoma tumors, probably due to the trapping mechanism of 18 F-FBPA in melanogenesis. This melanoma-preferential uptake of 18 F-FBPA was confirmed clinically by Morita et al [ 85 ]. 18 F-FBPA showed a slight washout pattern in squamous cell carcinoma of the head and neck ( n = 20) and a persistent pattern in malignant melanoma ( n = 8).…”

Section: Clinical Studiessupporting

confidence: 56%

“…Nariai et al indicated that in patients with malignant brain tumors the T / B ratio of 18 F-FBPA after a bolus injection of 18 F-FBPA had a significant linear correlation with the T / B ratio of 10 B estimated by 1-h constant infusion of 10 B-BPA, as simulated using the Runge–Kutta algorithm [ 84 ]. This type of quantitative evaluation has not been tried in other malignant tumors; however, Morita et al recently reported that the T / N ratios of 18 F-FBPA in head and neck cancers and malignant melanoma were not significantly changed over 120 min in spite of a slight decrease in 18 F-FBPA uptake [ 85 ]. In evaluating the T / N ratio of 18 F-FBPA in patients with head and neck cancers, it is notable that the uptake of 18 F-FBPA was higher in the dorsum tongue, submandibular gland, parotid gland, and tongue in this order among normal tissues in the oral and maxillofacial regions than in normal brain [ 86 ].…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research

Ishiwata

2019

Ann Nucl Med

View full text Add to dashboard Cite

4- 10 B-Borono-2- 18 F-fluoro- l -phenylalanine ( 18 F-FBPA) was developed for monitoring the pharmacokinetics of 4- 10 B-borono- l -phenylalanine ( 10 B-BPA) used in boron neutron capture therapy (BNCT) with positron emission tomography (PET). The tumor-imaging potential of 18 F-FBPA was demonstrated in various animal models. Accumulation of 18 F-FBPA was higher in melanomas than in non-melanoma tumors in animal models and cell cultures. 18 F-FBPA was incorporated into tumors mediated mainly by L-type amino acid transporters in in vitro and in vivo models. Tumoral distribution of 18 F-FBPA was primarily related to the activity of DNA synthesis. 18 F-FBPA is metabolically stable but is incorporated into melanogenesis non-enzymatically. These in vitro and in vivo characteristics of 18 F-FBPA corresponded well to those of 10 B-BPA. Nuclear magnetic resonance and other studies using non-radioactive 19 F- 10/11 B-FBPA also contributed to characterization. The validity and reliability of 18/19 F-FBPA as an in vivo probe of 10 B-BPA were confirmed by comparison of the pharmacokinetics of 18 F-FBPA and 10 B-BPA and direct measurement of both 18 F and 10 B in tumors with various doses of both probes administered by different routes and methods. Clinically, based on the kinetic parameters of dynamic 18 F-FBPA PET, the estimated 10 B-concentrations in tumors with continuous 10 B-BPA infusion were similar to those measured directly in surgical specimens. The significance of 18 F-FBPA PET was verified for the estimation of 10 B-concentration and planning of BNCT. Later 18 F-FBPA PET has been involved in 10 B-BPA BNCT of patients with intractable tumors such as malignant brain tumors, head and neck tumors, and melanoma. Usually a static PET scan is used for screening patients for BNCT, prediction of the distribution and accumulation of 10 B-BPA, and evaluation of treatment after BNCT. In some clinical trials, a tumor-to-normal tissue ratio of 18 F-FBPA > 2.5 was an inclusion criterion for BNCT. Apart from BNCT, 18 F-FBPA was demonstrated to be a useful PET probe for tumor diagnosis in nuclear medicine: better tumor-to-normal brain contrast compared with 11 C-methionine, differentiation of recurrent and radiation necrosis after radiotherapy, and melanoma-preferential uptake. F...

show abstract

Section: Clinical Studiessupporting

confidence: 56%

Section: Clinical Studiesmentioning

confidence: 99%

4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research

Ishiwata

2019

Ann Nucl Med

View full text Add to dashboard Cite

show abstract

“…18 F-BPA PET now has been widely used in patients with high-grade gliomas, , malignant meningioma, recurrent head and neck cancer, , and malignant melanomas in many investigations. This technology can accurately identify tumor lesions such as malignant brain tumors, which are difficult to judge by CT and MRI, and show the degree of malignant transformation.…”

Section: Imaging Methods Of Boron Macroimaging In Vivomentioning

confidence: 99%

The Development of Boron Analysis and Imaging in Boron Neutron Capture Therapy (BNCT)

et al. 2022

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a selective biological targeted nuclide technique for cancer therapy. It has the following attractive features: good targeting, high effectiveness, and causes slight damage to surrounding healthy tissue compared with other traditional methods. It has been considered as one of the promising methods for the treatment of various cancers. Measuring 10B concentrations is vital for BNCT. However, the existing technology and equipment cannot satisfy the real-time and accurate measurement requirements, and more efficient methods are in demand. The development of methods and imaging applied in BNCT to help measure boron concentration is described in this review.

show abstract

“…Therefore, BNCT links two fundamental approaches, i.e., chemotherapy and traditional radiotherapy. L-p-boronophenylalanine (L-BPA) has been clinically used for different kinds of cancers including malignant melanoma (6)(7)(8), malignant brain tumors (1,9,10), recurrent head and neck cancer (3,11,12), and malignant mesothelioma (13,14). Unlike other radiotherapy, the cytocidal effect of BNCT on tumor tissue relies on the selective uptakes of boron compounds in the tumors.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Pharmacokinetics of Boronophenylalanine and Its Uptakes in Gastric Cancer

et al. 2022

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT), a cellular-level particle radiation therapy, combines boron compounds selectively delivered to tumor tissue with neutron irradiation. Boronophenylalanine (BPA) is a boron compound widely used in malignant melanoma, malignant brain tumors, and recurrent head and neck cancer. However, neither basic nor clinical research was reported for the treatment of gastric cancer using BPA. Selective distribution of boron in tumors rather than that in blood or normal tissue prior to neutron irradiation is required for the successful treatment of BNCT. This study evaluated the pharmacokinetics and safety of 10B-labeled BPA (10B-BPA, abbreviated as BPA) and its uptakes in gastric cancer. Pharmacokinetics and safety were evaluated in Sprague–Dawley (SD) rats intravenously injected with BPA. The uptakes of boron in gastric cancer cell line MKN45 and in cell-derived xenografts (CDX) and patient-derived xenografts (PDX) animal models were measured. The results showed that the boron concentration in the blood of rats decreased fast in the first 30 min followed by a steady decrease following the observation time, having a half-life of 44.11 ± 8.90 min and an AUC-last of 815.05 ± 62.09 min×μg/ml. The distribution of boron in different tissues (heart, liver, lung, stomach, and small intestine) of rats revealed a similar pattern in blood except for that in the brain, kidney, and bladder. In MKN45 cells, boron concentration increased in a time- and concentration-dependent manner. In both CDX and PDX animal models, the boron is preferentially distributed in tumor tissue rather than in blood or normal tissues. In addition, BPA had no significant adverse effects in rats. Taken together, the results suggested that BPA revealed a fast decrease in boron concentration in rats and is more likely to distribute in tumor cells and tissue.

show abstract

Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection

Cited by 21 publications

References 28 publications

4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research

4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research

The Development of Boron Analysis and Imaging in Boron Neutron Capture Therapy (BNCT)

Evaluation of Pharmacokinetics of Boronophenylalanine and Its Uptakes in Gastric Cancer

Contact Info

Product

Resources

About